Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain

Tytuł:
Adherence to disease-modifying treatments in patients with multiple sclerosis in Spain
Autorzy:
Morillo Verdugo R
Ramírez Herráiz E
Fernández-Del Olmo R
Roig Bonet M
Valdivia García M
Temat:
Treatment adherence
oral administration
injectable administration
treatment satisfaction.
Medicine (General)
R5-920
Źródło:
Patient Preference and Adherence, Vol Volume 13, Pp 261-272 (2019)
Wydawca:
Dove Medical Press, 2019.
Rok publikacji:
2019
Kolekcja:
LCC:Medicine (General)
Typ dokumentu:
article
Opis pliku:
electronic resource
Język:
English
ISSN:
1177-889X
Relacje:
https://www.dovepress.com/adherence-to-disease-modifying-treatments-in-patients-with-multiple-sc-peer-reviewed-article-PPA; https://doaj.org/toc/1177-889X
Dostęp URL:
https://doaj.org/article/11b862a97f5c44b390bdf0963b26fa6e  Link otwiera się w nowym oknie
Numer akcesji:
edsdoj.11b862a97f5c44b390bdf0963b26fa6e
Czasopismo naukowe
Ramón Morillo Verdugo,1 Esther Ramírez Herráiz,2 Raquel Fernández-Del Olmo,3 Montserrat Roig Bonet,4 María Valdivia García51Valme University Hospital, Seville, Spain; 2La Princesa University Hospital, Madrid, Spain; 3Market Access Department, Roche Farma, S.A., Madrid, Spain; 4Project Department, Technical Advisory of Projects and Innovation “Esclerosis Múltiple España”, Madrid, Spain; 5Fundación de Esclerosis Múltiple Madrid, Madrid, Spain Purpose: Adherence to disease-modifying treatments is essential in order to maximize the beneficial effects of treatment for multiple sclerosis (MS). There are numerous treatments that have been approved. Treatment selection is essential in patient adherence. In addition, patient preference plays an increasingly significant role in treatment decision-making. This study aims to evaluate the degree of adherence, along with other variables that may influence this adherence, in Spain.Methods: A cross-sectional study was conducted with 157 MS patients with disease-modifying treatments. Adherence was assessed using the Morisky Green scale, and other related factors were measured using a questionnaire that addressed demographics, disease characteristics, global perception of pathology, impact of medication on patient’s life, and treatment decision-making.Results: The adherence rate was 71% and was associated with the following variables: older age, more treatments received, time to diagnosis 5–10 years, absence of exacerbations, better cognitive status, being married/in a union, clear information about the disease, and higher treatment satisfaction. The main cause for non-compliance was forgetfulness (27%). Conclusion: The adherence rate is acceptable. It is widely known that treatment satisfaction is related to adherence. In our study, patients’ level of satisfaction was higher with oral treatments. However, oral administration showed a greater lack of adherence. The main cause of lack of adherence was forgetfulness. In relation to other variables, cognitive status and family support showed a correlation with treatment adherence. Keywords: treatment adherence, oral administration, injectable administration, treatment satisfaction
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies